The Research Ethics Office at 725 Parkdale Avenue, Civic Campus is currently closed, and all staff are working remotely; all submissions (initial and post approval forms) should be submitted electronically via the Clinical Research Registration Form (CRRF) in IRIS.

New Research Studies:

• New studies related to COVID-19 should be submitted electronically in the Clinical Research Registration form in IRIS well as an email to Nancy Camack at ncamack@ohri.ca, Dr. Saginur at rsaginur@toh.ca, and Dr. Cameron at bcameron@toh.ca.
• All other new studies should be submitted electronically through IRIS.
• New studies unrelated to COVID-19 will continue to be reviewed; however, studies related to COVID-19 will be prioritized.
• If submitting a new application related to COVID-19, let your Research Ethics Coordinator or REBAdministration@toh.ca know immediately upon submission.

Signatures:

• For initial REB applications, the Principal Investigator, Co-Investigator and Department/Division Head signature pages can be digitally signed by the applicable party, or email confirmation can be uploaded into the application in lieu of the signature page.
• If the PI's signature is requested on a response to a Review Letter issued by the REB, the response letter can be digitally signed by the PI, or email confirmation from the PI can be provided.
• The REB's post approval forms (Amendment, Reportable Event, Continuing Review and Study Closure) include electronic sign offs – the signatory applies their signature by entering their TOH IT login email and password.

• Health Canada's Interim order respecting the importation and sale of medical devices for use in relation to COVID-19
• Health Canada's Notice to Clinical Trial Sponsors on the Management of Clinical Trials during the COVID-19 pandemic
• FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic